Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Cardiome Shares Remain Low On Merck’s Abandonment

By Myriad Equity Stock MarketsDec 19, 2012 06:35AM ET
www.investing.com/analysis/cardiome-shares-remain-low-on-merck%EF%BF%BD%EF%BF%BD%EF%BF%BDs-abandonment-148292
Cardiome Shares Remain Low On Merck’s Abandonment
By Myriad Equity   |  Dec 19, 2012 06:35AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
NDX
+0.12%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRCG
-4.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2070
+0.52%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIG
+0.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NWSA
-0.02%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CSII
-0.36%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Earlier in the year, specifically on March 19th 2012, shares of Vancouver based Cardiome Pharma Corp (CRME) dropped from $1.93/share or so to $.88/share in reaction to a press release regarding their partnership with the pharmaceutical giant Merck.

Merck was to officially discontinue development of the oral version of Cardiome’s flagship drug vernakalant, which left the IV formulation (referred to as vernakalant IV in the release). Merck apparently made the decision based on the regulatory environment, and the projected development timeline of vernakalant oral.

While there were some beneficial effects of this partnership termination, like significantly reduced development expenses and cash burn for Cardiome Pharma, investors did not like the fact that oral vernakalant was out of the picture.

According to CEO Doug Janzen’s statements, vernakalant oral also had a well-established profile for both efficacy and safety. As a long-term prevention treatment for atrial fibrillation, both Cardiome and the market seem to agree that an oral formulation would have been superior. Not only do oral formulations of drugs not have to deal with the invasiveness of IV formulations, but patients (and doctors) find them much easier and more convenient to administer. Whether or not Merck made the “right” decision is very debatable up to this point. For now, vernakalant oral is stuck in phase II development unless something can finance its progress later on.

Vernakalant IV has already been approved in Europe and Latin America and is marketed under the name BRINAVESS. Merck held commercial rights to this drug until September 26th 2012, when global marketing and development rights were returned to Cardiome – presumably after Merck did a bit more of their own research on the cardiovascular drug market.

While investors seemed to like the idea that Cardiome had regained the rights to its drug, the fact that Merck was so unimpressed by its prospects that it decided to basically dump the drug from its pipeline this year does bring up some concerns that should be considered by anyone that is considering an investment in this biotech stock.

While the prospects of any drug are never completely black or white, it’s important to realize that Merck must have seen something wrong (or at least lacking) with vernakalant. On the bright side for Cardiome, the patient population that could be using the drug as a long-term treatment to prevent atrial fibrillation is enormous (Cardiome’s research suggests that one out of every three patients admitted to hospitals for cardiac arrhythmia have atrial fibrillation).

Going forward, vernakalant has two major obstacles towards achieving its true potential. First is its troubled attempt at approval in the United States. Recall that vernakalant was put on clinical hold as far back as October 2010 by the FDA in the middle of its Phase III ACT V trial, which should bring up some concern on the drug’s safety and long-term chances of US approval.

The second is the fact that small pharmaceutical companies have big trouble with the marketing of drugs – especially those that target enormous drug markets. While Cardiome could theoretically do well by selling vernakalant IV by itself, Merck’s resources would have been extremely helpful.

Another indirect consequence of the misfortune that Cardiome has seen this year is related to its actual stock price. NASDAQ listing qualifications indicate that its stocks have to be above $1/share to prevent delisting. Cardiome is only trading at $.50/share as of yesterday’s closing bell, even after a substantial rally caused by a settlement of its debt obligations to Merck that was caused by the return of commercialization rights to vernakalant.

As dismal as the situation seems for Cardiome at this point, there is some hope of redemption for the stock. CRME would react quite well to news that the FDA removed its clinical hold on vernakalant IV. There is also a small chance that vernakalant could be scooped up cheaper by another pharmaceutical company that is willing to save Cardiome.

Still, the takeaway is that CRME seems very risky even though the stock has fallen so far. It’s in danger of a reverse stock split in the near future too, which is generally bad for shareholders due to negative perceptions that develop about biotech stocks that have to perform those reverse splits to regain NASDAQ compliance.
Cardiome Shares Remain Low On Merck’s Abandonment
 

Related Articles

Cardiome Shares Remain Low On Merck’s Abandonment

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email